August 1st 2025
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
Guiding Pharma Through Geopolitical Uncertainty: Q&A with the Federated Healthcare Advisory Panel
May 27th 2025In this Pharmaceutical Executive exclusive, Bob Jansen, David Shulkin, Gen. Paul Funk (Ret.), and Maj. Gen. Dennis LeMaster (Ret.)—members of the Federated Healthcare Advisory Panel—discuss how pharmaceutical companies can strengthen supply chain resilience, navigate policy shifts, and adopt a national security mindset.
Lykos Therapeutics Reshuffles Board of Directors Following FDA Rejection of Midomafetamine Capsules
January 15th 2025During the transition period, Lykos will work with a number of shareholders to secure financing for an additional Phase III trial of midomafetamine capsules for post-traumatic stress disorder.